8 pharma companies doubled lobbying spend in Q1

There were eight pharmaceutical companies that more than doubled their lobbying contributions in the first quarter of 2017 over the same period last year, according to a Kaiser Health News report.

The increased spending comes at a time when President Donald Trump has been critical of the drug industry and legislators including Sen. Bernie Sanders, I-Vt., John McCain, R-Ariz., and Rep. Elijah E. Cummins, D-Md., introduced bills aimed at lowering drug costs and allowing imports from Canada and other countries.

Last quarter the 38 major drug companies and trade organizations spent around $50.9 million, a more than $10 million increase over the first quarter of 2016. Here are the eight companies that more than doubled their spending on lobbying last quarter:

1. Celgene: 232 percent increase to $1 million
2. Horizon Pharma USA: 182 percent increase to $620,000
3. Shire Pharmaceuticals: 181 percent increase to $870,000
4. BioMarin Pharmaceuticals: 138 percent increase to $190,000
5. Mylan: 138 percent increase to $610,000
6. Teva Pharmaceuticals: 115 percent increase to $2.6 million
7. Vertex Pharmaceuticals: 114 percent increase to $450,000
8. Marathon Pharmaceuticals: 109 percent increase to $230,000

More articles on healthcare:
How these 3 trends will impact ASCs moving forward
20 best, worst US regions for children's healthcare
10 things to know about urologist compensation

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers